Amphetamine-Related Disorders Clinical Trial
Official title:
The Exploration of Novel Cross-frequency Protocol of Transcranial Alternating Current Stimulation in the Treatment of Methamphetamine Use Disorder: A Randomized Sham-controlled Study
The purpose of this research is to evaluate the efficacy of multiple sessions of theta-gamma cross-frequency transcranial alternating current stimulation in patients with methamphetamine (MA) use disorders.
Previous evidence suggests that different aspects of cognitive function are associated with activities of distinct EEG frequency bands. Gamma oscillatory has been found in clinical studies to reflect the processing of rewards in patients with drug dependence, whereas medial prefrontal theta oscillatory characterizes prefrontal response inhibition capacity to downstream reward arousal. Interestingly, impaired response inhibition or impaired evaluation of rewards in patients with drug dependence have been found to correlate with the arousal of psychological craving and the emergence of relapse. Here we aim to find causal evidence supporting these previous correlational findings by applying cross-frequency transcranial alternating current stimulation (tACS) in the specific frequency bands (theta-gamma) previously shown to be addiction-relevant. In a randomized control clinical trial design, we stimulate subjects with either theta-gamma or sham tACS. Electroencephalography will be collected before and after each treatment session. Besides, the scale and behavior task data will also collected before and after the treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02232789 -
Abuse Liability and Human Pharmacology of Mephedrone
|
Phase 1 | |
| Completed |
NCT01449565 -
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
|
Phase 2 | |
| Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
| Active, not recruiting |
NCT00100074 -
To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00033072 -
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
|
Phase 1 | |
| Completed |
NCT00990067 -
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
|
Phase 1 | |
| Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
| Recruiting |
NCT01899313 -
A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
|
N/A | |
| Active, not recruiting |
NCT00265278 -
Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00000350 -
Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
|
Phase 1 | |
| Active, not recruiting |
NCT00089440 -
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00040040 -
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
|
Phase 1 | |
| Completed |
NCT00040053 -
Ondansetron for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 | |
| Completed |
NCT00895804 -
Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)
|
Phase 1 | |
| Recruiting |
NCT03902405 -
Computerized Exercise to Alter Stimulant Approach Responses
|
N/A | |
| Recruiting |
NCT04982796 -
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
|
Phase 1/Phase 2 | |
| Completed |
NCT01386177 -
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
| Completed |
NCT01136278 -
Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
| Completed |
NCT00069251 -
Bupropion for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 | |
| Completed |
NCT01270672 -
Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)
|
N/A |